Scholars Central

Mini reviewPublished 29 Apr 2023

A review on cytotoxic drugs in neonates and infants

Authors: Rafael Forbes

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Neonatal and infant cancer is a rare but challenging condition. Significant physiological changes in the infant's first year, elevated rates of toxicity, mortality, and late effects complicate treatment. Portion improvement of chemotherapeutics might be a significant stage to further developing results. The majority of infant-use anticancer medications are dosed based on body size. However, dosing strategies are frequently inconsistent between tumor types and treatment protocols, and dose regimens are generally not based on evidence. We have compiled the pharmacological evidence that supports infant dosing regimens for a wide range of cytotoxic drugs in this review. A systematic review was carried out, and the available data were ranked according to a level of evidence (1–5) and a recommendation grade (A–D) based on consensus, with the appropriate dosing strategies indicated. There was sufficient pharmacological evidence to recommend a dosing algorithm for infants for nine of the 29 drugs (busulfan, carboplatin, cyclophosphamide, daunorubicin, etoposide, fludarabine, isotretinoin, melphalan, and vincristine) that received grade scores. There was sufficient evidence to recommend therapeutic drug monitoring in infants for busulfan and carboplatin.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in International Research Journal of Pharmacy and Pharmacology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalInternational Research Journal of Pharmacy and Pharmacology
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Rafael Forbes”